Literature DB >> 15516831

Inhibition of FGF receptor activity in glioma implanted into the mouse brain using the tetracyclin-regulated expression system.

Sylvain Miraux1, Sylvie Lemière, Raphael Pineau, Mauro Pluderi, Paul Canioni, Jean-Michel Franconi, Eric Thiaudière, Lorenzo Bello, Andreas Bikfalvi, Patrick Auguste.   

Abstract

We have investigated growth and vascularization of malignant glioma in mice upon conditional inhibition of fibroblast growth factor (FGF) receptor activity. C6 rat glioma cells were transfected with a dominant-negative fibroblast growth factor receptor-2 (FGFR2-DN) cDNA under the control of a tetracycline-regulated expression promoter (tet off) and implanted in the brain of immunodeficient mice. Magnetic resonance imaging analysis showed a significant decrease in tumor growth 14 days after implantation when FGFR2-DN was expressed compared to control. This size difference disappeared after 20 days. However, after 20 days, tumor and endothelial cells apoptosis were higher in the FGFR2-DN group and consequently angiogenesis was decreased whereas tumor cells were similarly associated with blood vessels at the tumor periphery. Pericyte coverage was not different between the two groups but a higher amount of pericytes not associated with vessels was found in the FGFR2-DN expressing group. This demonstrates, that conditional expression of inhibitor of FGF receptor activity in gliomas implanted in the brain of immunodeficient mice can be achieved efficiently, and that FGFs are major players in glioma development and in glioma angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15516831     DOI: 10.1007/s10456-004-1037-0

Source DB:  PubMed          Journal:  Angiogenesis        ISSN: 0969-6970            Impact factor:   9.596


  5 in total

1.  Local delivery of a synthetic endostatin fragment for the treatment of experimental gliomas.

Authors:  Gustavo Pradilla; Federico G Legnani; Giovanna Petrangolini; Pierangelo Francescato; Francesco Chillemi; Betty M Tyler; Sergio M Gaini; Henry Brem; Alessandro Olivi; Francesco DiMeco
Journal:  Neurosurgery       Date:  2005-11       Impact factor: 4.654

Review 2.  Antiangiogenic therapy in brain tumors.

Authors:  Sajani S Lakka; Jasti S Rao
Journal:  Expert Rev Neurother       Date:  2008-10       Impact factor: 4.618

Review 3.  Fibroblast Growth Factor Receptor Functions in Glioblastoma.

Authors:  Ana Jimenez-Pascual; Florian A Siebzehnrubl
Journal:  Cells       Date:  2019-07-13       Impact factor: 6.600

4.  Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition.

Authors:  Hendrik Fischer; Ninon Taylor; Sigrid Allerstorfer; Michael Grusch; Gudrun Sonvilla; Klaus Holzmann; Ulrike Setinek; Leonilla Elbling; Heidelinde Cantonati; Bettina Grasl-Kraupp; Christine Gauglhofer; Brigitte Marian; Michael Micksche; Walter Berger
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

5.  Tetracycline regulated systems in functional oncogenomics.

Authors:  Arkadiusz Welman; Jane Barraclough; Caroline Dive
Journal:  Transl Oncogenomics       Date:  2007-03-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.